image
Healthcare - Biotechnology - NASDAQ - US
$ 1.16
-4.92 %
$ 1.47 M
Market Cap
-0.08
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Mar, 2, 2025.

The intrinsic value of one KTTA stock under the worst case scenario is HIDDEN Compared to the current market price of 1.16 USD, Pasithea Therapeutics Corp. is HIDDEN

This DCF valuation model was last updated on Mar, 2, 2025.

The intrinsic value of one KTTA stock under the base case scenario is HIDDEN Compared to the current market price of 1.16 USD, Pasithea Therapeutics Corp. is HIDDEN

This DCF valuation model was last updated on Mar, 2, 2025.

The intrinsic value of one KTTA stock under the best case scenario is HIDDEN Compared to the current market price of 1.16 USD, Pasithea Therapeutics Corp. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
0 REVENUE
0.00%
-16 M OPERATING INCOME
-7.85%
-15.5 M NET INCOME
-11.27%
-13.4 M OPERATING CASH FLOW
7.80%
399 K INVESTING CASH FLOW
119.35%
-3.73 M FINANCING CASH FLOW
-16.22%
0 REVENUE
0.00%
-3 M OPERATING INCOME
23.84%
-3 M NET INCOME
22.41%
-3.12 M OPERATING CASH FLOW
22.74%
0 INVESTING CASH FLOW
0.00%
4.54 M FINANCING CASH FLOW
0.00%
Balance Sheet Pasithea Therapeutics Corp.
image
Current Assets 16.7 M
Cash & Short-Term Investments 16.3 M
Receivables 40.5 K
Other Current Assets 321 K
Non-Current Assets 9.42 M
Long-Term Investments 0
PP&E 220 K
Other Non-Current Assets 9.2 M
Current Liabilities 2.63 M
Accounts Payable 2.55 M
Short-Term Debt 81.7 K
Other Current Liabilities 0
Non-Current Liabilities 84.4 K
Long-Term Debt 0
Other Non-Current Liabilities 84.4 K
EFFICIENCY
Earnings Waterfall Pasithea Therapeutics Corp.
image
Revenue 0
Cost Of Revenue 648 K
Gross Profit -648 K
Operating Expenses 16 M
Operating Income -16 M
Other Expenses -472 K
Net Income -15.5 M
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-68.22% ROE
-68.22%
-61.12% ROA
-61.12%
-67.81% ROIC
-67.81%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Pasithea Therapeutics Corp.
image
Net Income -15.5 M
Depreciation & Amortization 648 K
Capital Expenditures -34.3 K
Stock-Based Compensation 592 K
Change in Working Capital 1.57 M
Others 842 K
Free Cash Flow -12.8 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Pasithea Therapeutics Corp.
image
KTTA has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Pasithea Therapeutics Corp.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 year ago
Jun 02, 2023
Bought 12.9 K USD
STEINMAN LAWRENCE
Director
+ 30000
0.431 USD
2 years ago
Oct 17, 2022
Bought 1.11 K USD
Delaney David
Director
+ 1000
1.11 USD
2 years ago
Sep 28, 2022
Bought 7.76 K USD
Camac Partners, LLC
director:
+ 6710
1.156 USD
2 years ago
Sep 29, 2022
Bought 7.76 K USD
Shahinian Eric
other: Member of 10% owner group
+ 6710
1.156 USD
2 years ago
Sep 28, 2022
Bought 68.5 K USD
Shahinian Eric
other: Member of 10% owner group
+ 57647
1.189 USD
2 years ago
Sep 06, 2022
Bought 24.6 K USD
Shahinian Eric
other: Member of 10% owner group
+ 21748
1.1326 USD
2 years ago
Sep 02, 2022
Bought 13.1 K USD
Shahinian Eric
other: Member of 10% owner group
+ 11507
1.1389 USD
2 years ago
Sep 01, 2022
Bought 62.6 K USD
Camac Partners, LLC
director:
+ 55646
1.1255 USD
2 years ago
Sep 01, 2022
Bought 62.6 K USD
Shahinian Eric
other: Member of 10% owner group
+ 55646
1.1255 USD
2 years ago
Aug 30, 2022
Bought 20.5 K USD
Shahinian Eric
other: Member of 10% owner group
+ 17828
1.1472 USD
2 years ago
Aug 29, 2022
Bought 20.5 K USD
Camac Partners, LLC
director:
+ 17828
1.1472 USD
2 years ago
Aug 29, 2022
Bought 5.84 K USD
Shahinian Eric
other: Member of 10% owner group
+ 5000
1.1681 USD
2 years ago
Aug 19, 2022
Bought 70.9 K USD
Leonite Capital LLC
director:
+ 54644
1.2982 USD
2 years ago
Aug 17, 2022
Bought 188 K USD
Camac Partners, LLC
director:
+ 155773
1.2087 USD
2 years ago
Aug 17, 2022
Bought 188 K USD
Shahinian Eric
other: Member of 10% owner group
+ 155773
1.2087 USD
7. News
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer Pasithea's PAS-004 Phase 1 trial advances to 22mg dose with no DLTs or rash, reinforcing its safety profile as a next-gen MEK inhibitor for NF1 and cancer. globenewswire.com - 3 weeks ago
Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4 -- Interim data from Cohort 4 expected Q1 2025 -- MIAMI, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced it has opened three clinical trial sites in Eastern Europe. These sites in Romania and Bulgaria are actively recruiting patients along with the four open sites in the United States, for Pasithea's PAS-004 Phase 1 trial. globenewswire.com - 1 month ago
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer -- SRC recommended that the trial escalate to the next dose level of 15mg capsule -- -- No dose-limiting toxicities (DLTs) observed to date -- -- No rash observed to date -- MIAMI, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced that the external Safety Review Committee recommended proceeding to cohort 4, 15mg capsule, without modifications. This recommendation was based on the absence of any dose limiting toxicities (DLT's). globenewswire.com - 3 months ago
Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules MIAMI, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 1,219,513 shares of its common stock (or pre-funded warrants in lieu thereof), accompanying Series A warrants to purchase up to 1,219,513 shares of common stock and accompanying short-term Series B warrants to purchase up to 1,219,513 shares of common stock at a purchase price of $4.10 per share (or per pre-funded warrant in lieu thereof) and accompanying warrants in a private placement priced at-the-market under the rules of the Nasdaq Stock Market. The Series A and the short-term Series B warrants will have an exercise price of $3.85 per share and will be exercisable immediately upon issuance. The Series A warrants will expire five years from the issuance date and the short-term Series B warrants will expire 18 months from the issuance date. The closing of the offering is expected to occur on or about September 30, 2024, subject to the satisfaction of customary closing conditions. globenewswire.com - 5 months ago
Why Is Pasithea Therapeutics Stock Surging On Thursday? On Thursday, Pasithea Therapeutics Corp.  KTTA announced safety, tolerability, pharmacokinetic (PK), and preliminary efficacy data from the first 2 cohorts of patients (n=6) in its Phase 1 trial of PAS-004 in patients with MAPK pathway-driven advanced solid tumors with a documented RAS, NF1 or RAF mutation or patients who have failed BRAF/MEK inhibition. benzinga.com - 5 months ago
Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer -- Single patient in 2mg cohort with stage 3 colon cancer who received 4 prior lines of therapy achieves prolonged stable disease and remains on drug into 6th dosing cycle -- -- No treatment-related adverse events (TRAEs) or dose-limiting toxicities (DLTs) observed to date, including no rash or gastrointestinal (GI) AEs -- -- Systemic exposure at steady-state enables constant target inhibition while avoiding peak plasma toxicities -- -- Half-life of approximately 70 hours supports once-daily or less frequent oral dosing -- -- Distinctive MEK inhibitor profile for the treatment of both NF1-related plexiform and cutaneous neurofibromas, cancer, and other opportunities -- MIAMI, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced safety, tolerability, pharmacokinetic (PK) and preliminary efficacy data from the first 2 cohorts of patients (n=6) in its Phase 1 clinical trial of PAS-004, being conducted at four clinical sites in the United States. globenewswire.com - 5 months ago
Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies Pasithea completes chronic toxicity studies for PAS-004, showing safety and potential for long-term use in NF1 and cancer treatment; Phase 1 trial ongoing globenewswire.com - 5 months ago
Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board Pasithea Tx appoints Dr. Rebecca Brown, an expert in Neurofibromatosis and Director at Mount Sinai, to its Scientific Advisory Board to aid in PAS-004. globenewswire.com - 5 months ago
Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference SOUTH SAN FRANCISCO, Calif. and MIAMI, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”) a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced that members of its management team will deliver a company presentation at the H.C. globenewswire.com - 6 months ago
Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting Pasithea to present preclinical data at ASCO 2024 showing PAS-004 superior inhibition of NRAS cancer cells and xenograft tumors compared to current MEKi's globenewswire.com - 9 months ago
Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting SOUTH SAN FRANCISCO, Calif. and MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the treatment of neurofibromatosis type 1 (NF1) and other indications, today announced the acceptance of an abstract for poster presentation at the American Society of Cancer Oncology (“ASCO”), which will be held in Chicago from May 31 – June 4, 2024. globenewswire.com - 10 months ago
Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024. globenewswire.com - 10 months ago
8. Profile Summary

Pasithea Therapeutics Corp. KTTA

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 1.47 M
Dividend Yield 0.00%
Description Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Contact 1111 Lincoln Road, Miami Beach, FL, 33139 https://www.pasithea.com
IPO Date Sept. 15, 2021
Employees 8
Officers Dr. Lawrence Steinman BA, M.D., Ph.D. Co-Founder, MD & Executive Chairman Mr. Daniel H. Schneiderman Chief Financial Officer Dr. Yassine Bendiabdallah Ph.D. Chief Operating Officer & Head of UK Clinics Dr. Graeme Currie Ph.D. Chief Development Officer Dr. Tiago Reis Marques M.D., Ph.D. Chief Executive Officer & Director